Predicting Lipid-Lowering Medication Persistence after the First Cardiovascular Disease Hospitalization

被引:1
作者
Hu, Feiyu [1 ]
Warren, Jim [1 ]
Exeter, Daniel J. [2 ]
机构
[1] Univ Auckland, Sch Comp Sci, Private Bag 92019, Auckland, New Zealand
[2] Univ Auckland, Sch Populat Hlth, Auckland, New Zealand
关键词
medication persistence; cardiovascular diseases; machine learning; prediction models; ARTIFICIAL NEURAL-NETWORK; CORONARY-HEART-DISEASE; SECONDARY PREVENTION MEDICATIONS; DECISION-SUPPORT-SYSTEM; MYOCARDIAL-INFARCTION; NEW-ZEALAND; LOGISTIC-REGRESSION; STATIN THERAPY; RISK-FACTOR; ADHERENCE;
D O I
10.1055/s-0040-1713905
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Objectives This study analyzed patient factors in medication persistence after discharge from the first hospitalization for cardiovascular disease (CVD) with the aim of predicting persistence to lipid-lowering therapy for 1 to 2 years Methods A subcohort having a first CVD hospitalization was selected from 313,207 patients for proportional hazard model analysis. Logistic regression, support vector machine, artificial neural networks, and boosted regression tree (BRT) models were used to predict 1- and 2-year medication persistence Results Proportional hazard modeling found significant association of persistence with age, diabetes history, complication and comorbidity level, days stayed in hospital, CVD diagnosis type, in-patient procedures, and being new to therapy. BRT had the best predictive performance with c-statistic of 0.811 (0.799-0.824) for 1-year and 0.793 (0.772-0.814) for 2-year prediction using variables potentially available shortly after discharge. Conclusion The results suggest that development of a machine learning-based clinical decision support tool to focus improvements in secondary prevention of CVD is feasible.
引用
收藏
页码:61 / 74
页数:14
相关论文
共 50 条
[31]   Identifying Clusters of Adherence to Cardiovascular Risk Reduction Behaviors and Persistence with Medication in New Lipid-Lowering Drug Users. Impact on Healthcare Utilization [J].
Malo, Sara ;
Jose Rabanaque, Maria ;
Maldonado, Lina ;
Moreno-Franco, Belen ;
Chaure-Pardos, Armando ;
Jesus Lallana, Maria ;
Pilar Rodrigo, Maria ;
Aguilar-Palacio, Isabel .
NUTRIENTS, 2021, 13 (03) :1-15
[32]   Lipid-lowering therapy for the prevention of atherosclerotic cardiovascular disease: guidelines and clinical practice [J].
Lucchi, Tiziano ;
Cesari, Matteo ;
Vergani, Carlo .
GIORNALE ITALIANO DI CARDIOLOGIA, 2020, 21 (04) :256-263
[33]   Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease [J].
Karalis, Dean G. .
CURRENT OPINION IN LIPIDOLOGY, 2023, 34 (06) :252-258
[34]   Racial differences in lipid-lowering agent use in Medicaid patients with cardiovascular disease [J].
Litaker, D ;
Koroukian, SM .
MEDICAL CARE, 2004, 42 (10) :1009-1018
[35]   Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods [J].
Yin, Wei-Hsian ;
Wu, Chau-Chung ;
Chen, Jaw-Wen .
INTERNATIONAL JOURNAL OF GERONTOLOGY, 2012, 6 (04) :241-246
[36]   'Keep on keeping on': persistence with lipid-lowering treatment in familial hypercholesterolaemia [J].
Hegele, Robert A. .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 30 (04) :318-319
[37]   Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer [J].
Morofuji, Yoichi ;
Nakagawa, Shinsuke ;
Ujifuku, Kenta ;
Fujimoto, Takashi ;
Otsuka, Kaishi ;
Niwa, Masami ;
Tsutsumi, Keisuke .
PHARMACEUTICALS, 2022, 15 (02)
[38]   Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events [J].
Raggi, Paolo ;
Becciu, Maria Laura ;
Navarese, Eliano P. .
CURRENT OPINION IN LIPIDOLOGY, 2024, 35 (03) :110-116
[39]   Secular trends in lipid-lowering treatment and lipid levels after a first acute myocardial infarction [J].
Bjorck, Lena ;
Welin, Catharina ;
Rosengren, Annika .
VASCULAR HEALTH AND RISK MANAGEMENT, 2007, 3 (06) :1045-1051
[40]   Lipid-lowering treatment in secondary prevention of ischaemic cerebrovascular disease [J].
Climent, Elisenda ;
Benaiges, David ;
Pedro-Botet, Juan .
CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2020, 32 (04) :175-182